First Patient Treated Worldwide with Accuray's New TomoHDA™ System
SUNNYVALE, California, June 5, 2013
-- Advanced Radiation Treatment Now Available to Cancer Patients in France
SUNNYVALE, California, June 5, 2013 /PRNewswire/ -- Accuray Incorporated
(Nasdaq: ARAY), announced today the first patient has been treated with its
new TomoHDA™ System at Centre Oscar Lambret in Lille, France. Building upon
the proven TomoTherapy® Hi-Art® and TomoHD™ technologies, the TomoHDA System
is a fully-integrated radiation therapy system designed to treat the full
spectrum of cancer patients. Performance enhancements, unrivaled dose
distributions and faster treatments are among the multiple new benefits of the
TomoHDA System. With the addition of this latest innovation in the TomoTherapy
family, Centre Oscar Lambret will be capable of providing excellent care to
more patients as a result of the TomoHDA System's increased speed when
computing treatment plans and delivering radiation treatment.
"Last month we successfully treated a breast cancer patient with our new
TomoHDA. When it comes to cancer care, we are selective in the investments we
make and only choose treatments that we believe will make a difference in the
quality of care we provide to patients," said Prof. Eric Lartigau, M.D.,
Ph.D., Centre Oscar Lambret. "We are equipping our clinicians with the new
TomoHDA technology on top of our two existing TomoTherapy Systems and
CyberKnife System, because we believe it is a true innovation that has the
potential to optimize cancer care for the full spectrum of cancer patients we
treat, especially those battling breast cancer."
Centre Oscar Lambret is a leader in radiation oncology treatment with three
TomoTherapy Systems on-site and a CyberKnife System. All three TomoTherapy
Systems are equipped with VoLO™ Technology, offering real-time efficiency for
treatment planning and dose calculation. VoLO Technology relies on high-end
graphics processing unit (GPU) hardware and software that leverage the GPU's
parallel processing abilities to perform dose calculation and optimization in
a matter of minutes even for the most complex cases.
"Accuray's significant enhancements to its TomoTherapy and CyberKnife
radiation oncology systems have been well-received across Europe with centers
in Germany and now France acquiring them in recent months," said Lionel
Hadjadjeba, general manager for Europe, India, Middle East, Africa (EIMEA) and
senior vice president of International Business at Accuray. "Accuray looks
forward to working closely with these centers to ensure patients continue to
receive the best possible care."
"Evidenced by Centre Oscar Lambret's adoption of three TomoTherapy Systems and
a CyberKnife System, the center clearly recognizes the value Accuray's
technologies bring to cancer care," said Joshua H. Levine, president and chief
executive officer of Accuray. "Centre Oscar Lambret's decision to invest
deeply in Accuray's radiation oncology treatment solutions helps cement its
worldwide leadership in cancer treatment and national clinical programs and is
in line with their ongoing missions toward care, research and academic
teaching and training."
The new TomoHDA System is equipped with the VoLO Technology as well the
TomoEDGE™ Dynamic Jaws technology making it the gold standard for image-guided
IMRT (intensity-modulated radiation therapy) treatment, offering faster
treatments. The new TomoEDGE technology allows for sharper dose sculpting and
reduces treatment time for many patients by approximately half, which will
enable clinics to treat more patients per day. Additionally through the use of
3D daily imaging of the tumor site throughout a patient's course of radiation
treatment, physicians often use the information to make important changes to
treatment plans ensuring optimal delivery of radiation to only the tumor site,
sparing surrounding critical structures and healthy tissue.
About Centre Oscar Lambret Centre Oscar Lambret cancer centre is the regional
reference centre of the North French region. Its four oncology missions are
care, research and academic teaching and training. The radiation therapy
department is headed by Prof. Lartigau, M.D., Ph.D. and Director in charge of
research, scientific cooperation and University relations. The radiation
department treats 3,500 new patients every year. For more information on
Centre Oscar Lambret, please visit http://www.centreoscarlambret.fr/ .
About Accuray Accuray Incorporated (Nasdaq: ARAY), is a radiation oncology
company that develops, manufactures and sells personalized, innovative
treatment solutions that set the standard of care with the aim of helping
patients live longer, better lives. The Company's leading-edge technologies
deliver the full range of radiation therapy and radiosurgery treatments. For
more information, please visit www.accuray.com .
Safe Harbor Statement Statements made in this press release that are not
statements of historical fact are forward-looking statements and are subject
to the "safe harbor" provisions of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements in this press release relate, but are
not limited, to clinical applications, dose distributions, treatment times,
clinical results, patient outcomes, and the Company's leadership position in
radiation oncology innovation. Forward-looking statements are subject to risks
and uncertainties that could cause actual results to differ materially from
expectations, including risks detailed from time to time under the heading
"Risk Factors" in the company's report on Form 10-K filed on September 10,
2012, as updated in our Form 10-Qs filed on November 8, 2012, February 6,
2013, and May 9, 2013 and as updated periodically by our other filings.
Forward-looking statements speak only as of the date the statements are made
and are based on information available to the Company at the time those
statements are made and/or management's good faith belief as of that time with
respect to future events. The Company assumes no obligation to update
forward-looking statements to reflect actual performance or results, changes
in assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities laws.
Accordingly, investors should not place undue reliance on any forward-looking
Contact: Rebecca Phillips, Public Relations Manager, Accuray, +1-408-716-4773,
firstname.lastname@example.org, or Helen Shik, Schwartz MSL, +1-781-684-0770,
Press spacebar to pause and continue. Press esc to stop.